Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Early Phase 1
4(66.7%)
Phase 1
2(33.3%)
6Total
Early Phase 1(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07556653Early Phase 1Not Yet Recruiting

Allogeneic WTX-212C in Advanced Solid Tumors

Role: collaborator

NCT07269899Phase 1Recruiting

A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors

Role: collaborator

NCT06528249Phase 1Not Yet Recruiting

Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies

Role: collaborator

NCT05707325Early Phase 1Recruiting

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

Role: lead

NCT06106152Early Phase 1Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Role: collaborator

NCT05800041Early Phase 1Unknown

A Exploratory Trial of WTX221 in Refractory Gout Patients

Role: collaborator

All 6 trials loaded